Almirall

GW receives Austrian approval for cannabis-based oral spray for MS

Friday, February 10, 2012 12:04 PM

GW Pharmaceuticals’ Sativex (THC and cannabidiol) oral spray has received regulatory approval in Austria as a treatment of spasticity due to Multiple Sclerosis (MS).

More... »


Almirall and Galapagos enter into research alliance

Friday, January 27, 2012 01:57 PM

Barcelona, Spain-basedAlmirall has formed a research alliance with BioFocus, an affiliate of Galapagos. The three-year collaboration is aimed at delivering drug development candidates directed to a key respiratory target of interest to Almirall. 

More... »


Almirall partners with Proteros

Monday, September 26, 2011 12:31 PM

Spain's Almirall and Proteros of Germany have linked up to develop a treatment in the field of inflammatory diseases, according to PharmaTimes.

More... »

Nycomed and Almirall partner to market COPD drug

Thursday, May 5, 2011 11:54 AM

Nycomed and Almirall will become marketing partners for the chronic obstructive pulmonary disease (COPD) treatment Daxas. The two firms have entered into a co-branding agreement covering Spain for Daxas (roflumilast), Nycomed's once-daily COPD tablet, according to Pharma Times.

More... »

Sativex available in Spain for MS

Thursday, March 17, 2011 01:24 PM

Almirall says Sativex is available to health professionals and patients in hospital pharmacies in Spain. It is the first specific treatment for spasticity in Multiple Sclerosis (MS) patients who have not responded adequately to other treatments. Sativex is administered as oromucosal spray enabling flexible dosage, which is particularly appropriate given the variable nature of spasticity and MS itself. It is an endocannabinoid modulator made of two actives: THC (delta-9-tetrahidrocannabinol) and CBD (cannabidiol).

More... »


CWWeekly

May 21

Parexel consultant testifies on FDA biosimilars guidance

Global Telecom Testing checks worldwide toll-free phone lines for multinational clinical trials

To read the full articles for this issue of CWWeekly, please click here for subscription information.

Already a digital subscriber? Access this issue now.

CWWeekly

May

Newer sites most optimistic about the future
Investigative sites of all sizes, from part-time physician-run sites to large dedicated research centers, report a rebound in operating conditions, according to a new CenterWatch analysis, yet sites from each subgroup indicate they have concerns…

Risk-based monitoring slow to catch on with industry
It's estimated that the cost of physically sending monitors to all investigative sites at regular intervals, a model the industry itself developed and has adhered to for about a decade, eats up one-third to one-half of…

Eye On Millennium
Millennium, The Takeda Oncology Company, discovers and develops novel treatments applying world-class recombinant technology to a wide variety of oncology disease targets…

To read the full articles for this issue of The CenterWatch Monthly, please click here for subscription information.

Already a digital subscriber? Access this issue now.

JobWatch centerwatch.com/jobwatch

Featured Jobs